Gamma Knife Stereotactic radiotherapy combined with tislelizumab as later-line therapy in pMMR/MSS/MSI-L metastatic colorectal cancer: A Phase II Trial Analysis

Yiran Zhang[1,2*], Hanyang Guan[1*], Shijin Liu[1*], Haoquan Li[1], Zili Bian[1], Jiashuai He[1], Zhan Zhao[1], Shenghui Qiu[1], Tianmu Mo[1], Xiangwei Zhang[1], Zuyang Chen[1], Hui Ding[1], Xiaoxu Zhao[1], Liang Wang[3#], Yunlong Pan[1,4#], Jinghua Pan[1#]

1. Department of General Surgery, The First Affiliated Hospital of Jinan University, 510632, Guangzhou, Guangdong, P. R. China
2. Department of Body Gamma Knife, The First Affiliated Hospital of Jinan University, 510632, Guangzhou, Guangdong, P. R. China
3. Department of Oncology, The First Affiliated Hospital of Jinan University, 510632, Guangzhou, Guangdong, P. R. China
4. MOE Key Laboratory of Tumor Molecular Biology and Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes. Institute of Life and Health Engineering, Jinan University, Guangzhou, China.

*These authors contributed equally

Running title: Combined SBRT and Immunotherapy in pMMR mCRC.

#Corresponding author:
Jinghua Pan, Department of General Surgery, The First Affiliated Hospital of Jinan University, 510632, Guangzhou, Guangdong, P. R. China; E-mail: huajanve@foxmail.com
Yunlong Pan: Department of General Surgery, The First Affiliated Hospital of Jinan University, 510632, Guangzhou, Guangdong, P. R. China; E-mail: tpanyl@jnu.edu.cn
Liang Wang: Department of Oncology, The First Affiliated Hospital of Jinan University, 510632, Guangzhou, Guangdong, P. R. China. E-mail: wangliang@jnu.edu.cn.

Conflict of interest: The authors disclosed no potential conflicts of interest.

Abstract

An immunosuppressive tumor microenvironment limits the efficacy of immunotherapy, thus patients

with MSS and pMMR mCRC often face great challenges.In this phase II trial, patients received

Gamma Knife SBRT combined with Tislelizumab. P Biomarker analysis was performed pre- and

post-treatment. From November 2022 to July 2024, 13 of 20 patients achieved PR, 6 achieved SD.

mPFS was 10.7 months (95% CI, 6.4-15.0). With no grade 4 events noted, common adverse events

included nausea (65%), anemia (55%), and fatigue (45%). RNA sequencing indicated enhanced

immune infiltration in PR patients. For patients with pMMR/MSS/MSI-L mCRC who had not

responded to first and second-line therapies, the combo of Gamma Knife SBRT and tislelizumab

showed high efficacy and reasonable safety. Significant post-radiotherapy improvements in the

tumor's immunosuppressive microenvironment, including lower fibrosis, normalizing of tumor

vasculature, and activation of the PD-1/PD-L1 checkpoint pathway were revealed by biomarker

analysis. These results imply that patients with pMMR/MSS/MSI-L mCRC who were unresponsive to

the first and second-line chemotherapy, Gamma Knife SBRT with tislelizumab provides a safe and

powerful later-line treatment alternative. The study is registered with ClinicalTrials.gov (identifier:

ChicTR2200011777).

Keywords: Gamma Knife Stereotactic body radiation therapy; mismatch repair-proficient;

tislelizumab; Metastatic colorectal cancer; Immune checkpoint inhibitors; PD-L1.

Statement of significance

This study offers a safe and powerful option for pMMR/MSS/MSI-L mCRC patients fail to first and

second-line chemotherapy. And discover Gamma Knife SBRT contributed to potentially converting

the suppressive "cold" tumor immune microenvironment into an activated "hot" microenvironment

conducive to immunotherapy efficacy in pMMR CRC.

Introduction

Colorectal cancer continues to represent a significant threat to life. As reported in the 2020 Global

Cancer Statistics, colorectal cancer accounts for 10% of all cancer cases, ranking third in incidence,

while its mortality rate is 9.4%, second only to lung cancer (1,2). Especially, 20% of newly diagnosed

colorectal cancer patients present show metastases, and 40% have recurrence and metastases after

local treatment (3). The FOLFOX/FOLFIRI chemotherapy regimen, which comprises oxaliplatin,

5-fluorouracil, and irinotecan is the mainstay of clinical treatment for metastatic colorectal cancer

(mCRC). For patients harboring wild-type RAS and BRAF, the addition of the epidermal growth factor

receptor (EGFR) inhibitor cetuximab is recommended(4,5). For patients with RAS mutations, the

anti-angiogenic agent bevacizumab is advised. Nevertheless, RAS-mutant patients exhibit poorer

prognoses and shorter survival times compared to their wild-type counterparts (6,7). The efficacy of

chemotherapy in combination with targeted therapy remains suboptimal (7).

The development of immune checkpoint inhibitors (ICIs) transforms cancer immunotherapy (8).

Particularly CRCs with mismatch repair deficiency (dMMR) and high microsatellite instability (MSI-H)

show a strong response to ICIs (9). But most CRC cases are either microsatellite-stable/low

microsatellite instability (MSS/MSI-L) or mismatch repair-profile (pMMR), which reduces the efficacy

of immunotherapy in a significant number of mCRC patients (9). Chemotherapeutic agents can

cause immunogenic cell death in tumors, thus coordinating with ICIs improves anti-tumor efficacy

(10). Additionally, anti-angiogenic therapies targeting VEGFR facilitate the normalization of tumor vasculature and promote immune cell infiltration, subsequently amplifying immune-mediated tumor eradication (11). Clinical studies, however, have revealed that t combining mFOLFOX6 or other chemotherapy regimens with anti-VEGF, anti-EGFR, and ICIs does not produce better clinical outcomes in mCRC (12,13). Consequently, identifying alternative strategies to augment the efficacy of immunotherapy remains a pivotal objective in the field of cancer immunotherapy in pMMR/MSS/MSI-L mCRC.

Stereotactic body radiation therapy (SBRT), effectively targets and eradicates tumor cells with high-dose radiation (14). Although traditional radiotherapy is sometimes linked with immunosuppressive effects (15), SBRT's exact targeting can expose tumor neoantigens, mobilize and activate immune cells, increase their infiltration into the tumor, and improve the tumor immune microenvironment (16,17). The Gamma Knife is a principal modality in SBRT, employing gamma rays generated by cobalt-60 to deliver a single, high-dose focused irradiation to the target lesion. The Gamma Knife provides several benefits over conventional radiotherapy, including hiexact stereotactic targeting, increased delivery dose to the lesion, prevention of accelerated repopulation of tumor cells, and better local control rates of tumors(18). Our team firstly observed a case with pMMR-type mCRC who exhibited local recurrence and distant metastasis following first-line and second-line chemotherapy combined with targeted therapy(19). After undergoing gamma knife SBRT followed by tislelizumab treatment, intrahepatic metastatic lesions were reduced and stabilized, the patient showed a partial response (PR) with notable reduction of recurrent lesions in the rectal wall and stabilization of intrahepatic metastases, so extending the progression-free survival (PFS)

exceeded beyond 3 months (19). These findings suggest that Gamma Knife SBRT might improve ICBs sensitivity in mCRC.

The results of a phase II clinical trial assessing the combination of Gamma Knife SBRT combined with tislelizumab as a later-line therapy in patients with pMMR/MSS/MSI-L mCRC are presented in this report together with safety and efficacy. NanoString assay for transcriptome analysis was employed to elucidate changes in the tumor immune microenvironment during the combined treatment, offering insights into the therapeutic potential and mechanistic underpinnings of this integrated approach.

Results

Patients

In this clinical trial, twenty patients with pMMR/MSS/MSI-L tumors refractory to first or second-line treatment were enrolled. The cohort comprised 15 males and 5 females, with ages ranging from 47 to 77 years. Predominantly, the primary tumors were located in the left colon and rectum (17/20, 85%), with the liver being the most common site of metastasis, followed by the lung (3/20)(**Table 1**). Flowchart of therapeutic regimen and flow diagram of enrolled participants in the study were shown in **Figure 1A** and **Figure 1B.**

Molecular profiling revealed RAS mutations in 11 patients (55%), with 5 exhibiting KRAS mutations and 6 presenting NRAS mutations. PD-L1 expression was assessed in 18 patients, 12 (60%) patients had combined positive score (CPS) ≤ 1. Tumor mutation burden (TMB) data were

132 available for 8 patients, with a median TMB of 4.62 mutations/Mb (IQR 3.08-8.97). Notably, only one

133 patient exhibited a TMB > 10 mutations/Mb (**Table 1**).

Characteristics	Patients (n=20)
Age, years, median (IQR), n (%)	60 (56-65)
<60	8 (40%)
≥60	12 (60%)
Sex, n(%)	
Male	15 (75%)
Female	5 (25%)
ECOG performance status, n (%)	
0	12 (60%)
1	8 (40%)
Primary tumor location, n (%)	
Left colon and rectum	17 (85%)
Right colon	3 (15%)
Number of metastatic organs[a], n (%)	
1	14 (70%)
≥2	6 (30%)
Metastatic organ, n (%)	
Liver	14 (70%)
Lung	7 (35%)
Lymph node	2 (10%)
Other	3 (15%)
Ras mutation type, n (%)	
KRAS	5 (25%)
NRAS	6 (30%)
Other	9 (45%)
PD-L1 expression, CPS, n (%)	
CPS≤1	12 (60%)
CPS > 1	6 (30%)
Unknown	2 (10%)
TMB (mut/Mb), median (IQR), n (%)	4.62 (3.08-8.97)
TMB<5	4 (20%)
TMB≥5, ≤10	3 (15%)
TMB>10	1 (5%)
Unknown	12 (60%)

Table 1: Baseline demographic and clinical characteristics.

Efficacy

In our cohort of 20 patients meeting inclusion criteria, 13 (65%) achieved a partial response (PR),

and 6 (35%) maintained stable disease (SD), resulting in a robust disease control rate (DCR) of 95%

(**Table 2**). Patients with liver metastases achieved 92.9% DCR, and patients with metastases in

non-liver locations notably achieved a remarkable 100% DCR, only 1 patient with liver metastases

experienced disease progression (PD) (**Figure 2A**), As of the data cutoff date, 7 patients remained

on maintenance treatment, and 1 patient underwent surgery due to disease progression (**Figure 2A**).

Remarkably, 3 patients refractory to first-line treatment responded to SBRT combined with

tislelizumab, achieving rapid regression to NED status, with durations ranging from 6 to 18 months

before progression. Encouragingly, 1 patient remains in a state of NED, under ongoing monitoring

(**Figure 2A**).

	All patients (N = 20)	Liver metastasis (N = 14)	Other metastasis (N = 6)
Best overall response			
Complete response (CR), n (%)	0 (0%)	0 (0%)	0 (0%)
Partial response (PR), n (%)	13 (65%)	8 (57%)	5 (83%)
Stable disease (SD), n (%)	6 (30%)	5 (36%)	1 (17%)
Progressive disease (PD), n (%)	1 (10%)	1 (7%)	0 (0%)
ORR, n (%, 95% CI)	13 (65%, 40.8-84.6%)	8 (57.1%, 28.9-82.3%)	5(83.3%, 35.9-99.6%)

| DCR, n (%, 95% CI) | 19 (95%, 75.1-99.9%) | 13 (92.9%, 66.1-99.8%) | 6(100%, 54.1-100%) |

Abbreviations: ORR, objective response rate; DCR, disease control rate.

Table 2: Efficacy outcomes.

Most patients exhibited favorable survival outcomes throughout the treatment (**Figure 2B**), and

median progression-free survival (PFS) was 10.7 months (95% CI, 6.4, 15.0) (**Figure 2C**).

Additionally, a comparative survival analysis included 23 patients who underwent first and

second-line treatment and Gamma Knife SBRT without immunotherapy, revealing a median PFS of

6.7 months (95% CI, 5.6, 7.0), this data shown Gamma Knife SBRT combined with tislelizumab as

later-line treatment prolong PFS in mCRC (Log-rank test = 5.638, P = 0.0176) (**Figure 2D**). These

findings suggest Gamma Knife SBRT combined with tislelizumab can effectively inhibiting mCRC

progression.

In our analysis of clinical characteristics and patient prognosis, we observed that the median

progression-free survival (mPFS) of patients with wild-type RAS expression was significantly longer

(14 months) compared to those with KRAS (7.3 months) and NRAS (5 months) mutations (**Figure**

2-figure supplementary1 A). These results are consistent with prior studies indicating that RAS

mutations are associated with increased malignancy, diminished therapeutic response, and poorer

overall prognosis in colorectal cancer. However, statistical analysis did not reveal a significant

difference between the groups (Log-rank test = 4.278, P = 0.118), which may be attributed to the

limited sample size and other factors inherent to the study design. Additionally, we assessed the PFS

of patients with simple liver metastases versus those with metastases to other organs (**Figure**

2-figure supplementary1 B). Notably, the mPFS of patients with liver metastases (13 months) was

longer than that of those with metastases at other sites (8.5 months). This difference could potentially

be explained by the efficacy of localized gamma knife treatment in managing liver metastases.

Despite this observation, statistical comparison between the two groups did not yield a significant

difference (Log-rank test = 0.081, P = 0.776). Given these limitations, further investigation with larger

sample sizes is essential to elucidate the factors contributing to these trends and to confirm the

clinical significance of these findings.

In light of the abscopal effect of radiotherapy, we extended our observations beyond the lesions

directly targeted by stereotactic radiotherapy to include non-irradiated lesions (**Figure 2-figure**

supplementary1 C). Imaging examinations revealed significant tumor regression in both the

irradiated target lesions (**Figure 2E, F**) and the non-irradiated lesions (**Figure 2E, G**) following

Gamma Knife SBRT combined with tislelizumab. These findings suggest that SBRT not only

impacts the irradiated lesions but also sensitize distant metastatic sites for ICBs through the

abscopal effect, thereby enhancing the systemic antitumor response when combined with

immunotherapy.

Safety

All 20 enrolled patients received the assigned treatment regimen, with safety assessments

conducted every three treatment cycles. Treatment-related adverse events (TRAEs) and

immune-related adverse events are summarized in **Table 3.** Predominantly, patients experienced

mild to moderate adverse events, with the most common being nausea (65%), anemia (55%),

electrolyte disturbances (55%), fatigue (45%), and anorexia (35%). Notably, only two patients

experienced grade 3 events of increased blood bilirubin, while no grade 4 adverse events were

reported throughout the study period.

TEAEs, n (%)	Patient (N=20)				
	Grade 1	Grade 2	Grade 3	Grade 4	Any grade
Anemia	9 (45%)	2 (10%)	0	0	11 (55%)
Neutropenia	1 (5%)	0	0	0	1 (5%)
Nausea	10 (50%)	3 (15%)	0	0	13 (65%)
Poor appetite	3 (15%)	4 (20%)	0	0	7 (35%)
Electrolyte disturbance	7 (35%)	2 (10%)	0	0	11 (55%)
Hand-foot syndrome	0	0	0	0	0
Leukocytopenia	2 (10%)	0	0	0	2 (10%)
Aspartate transaminase increased	2 (10%)	2 (10%)	0	0	4 (20%)
Lipase increased	0	0	0	0	0
Proteinuria	0	0	0	0	0
Thrombocytopenia	2 (10%)	2 (10%)	0	0	4 (20%)
Vomiting	1 (5%)	3 (15%)	0	0	4 (20%)
Hypothyroidism	0	0	0	0	0
Triglycerides increased	0	0	0	0	0
Fatigue	6 (30%)	3 (15%)	0	0	9 (45%)
Blood bilirubin increased	0	0	2 (10%)	0	2 (10%)
Alanine transaminase increased	2 (10%)	1 (5%)	0	0	3 (15%)
Peripheral neurotoxicity	0	0	0	0	0
Hoarseness	0	0	0	0	0
Rash	4 (20%)	0	0	0	4 (20%)
Thyroiditis	0 (0%)	0	0	0	0
Diarrhea	1 (5%)	0	0	0	1 (5%)
Troponin increased	0	0	0	0	0
Fever	0	0	0	0	0
Alkaline phosphatase increased	0	0	0	0	0
Amylase increased	0	0	0	0	0
Hypertension	0	0	0	0	0

Table 3: Treatment-emergent adverse events (TEAEs) since the initiation of protocol-specified treatment

Identification of differentially expressed genes between responder and non-response groups

To elucidate the impact of the tumor immune microenvironment on combination therapy outcomes,

we employed NanoString assay for transcriptome analysis of tumor samples obtained from 16

enrolled patients before and after treatment, totaling 32 samples (**Figure 3A**). Patients were stratified

into responder (PR) and non-responder (non-PR) groups based on treatment outcomes. Gene

expression differential analysis between pre- and post-treatment samples within each group

identified significant alterations, detailed in the **Source data** and illustrated in **Figure 3B.**

Our findings highlighted notable up-regulation of key genes involved in antigen presentation (CD40,

TNFSF18, TNFSF4), immune checkpoint modulation (PDCD1LG2, CD274, IDO1, VTCN1), and T

cell activation pathways (TNFRSF9, CD28, ICOS, CD40LG, CD2, GZMK, ENTPD1, ITGAE) in the

responder group. Additionally, a diverse array of chemokine family genes (IL2, IL4, IL17A, CCR2,

CCL22) showed enhanced expression in PR group (**Figure 3B**). Furthermore, immune cell

abundance analysis based on 11 predefined immune cell types revealed significantly elevated levels

in the PR group compared to non-PR. included T cells, B cells, mast cells, macrophages, Dendritic

Cell (DC), Cytotoxic cells, NK CD56 cell, CD8 T cell, CD45 cell, Th1 cells and NK cell (**Figure 3C**).

This heightened immune activation in responders encompassed robust antigen presentation, T cell

activation, and co-stimulation processes crucial for effective immune-mediated tumor control.

To investigate the impact of Gamma Knife treatment on patient outcomes, we conducted a

differential expression analysis of pre- and post-treatment samples from both responder (PR) and

non-responder (non-PR) groups (**Figure 3-figure supplementary1 A**). The results revealed limited

gene expression alterations following treatment. However, intersecting the differentially expressed

genes from both groups identified NOS2 as a gene that was consistently upregulated post-treatment

in both cohorts (**Figure 3-figure supplementary1 B**). Although NOS2's increased expression may

be associated with Gamma Knife treatment, its potential role in colorectal cancer treatment remains

underexplored, warranting further investigation to elucidate the underlying mechanisms.

Additionally, to identify genes linked to treatment efficacy, we performed univariate and multivariate

Cox regression analyses on the expression levels of 289 genes from sequencing data in relation to

disease progression. Unfortunately, due to the limited sample size and sequencing depth, neither

analysis yielded statistically significant results. The full Cox regression analysis of these genes is

provided in the **Supplementary File1**.

Following the combination of stereotactic radiotherapy and immunotherapy, a striking reduction in

liver metastasis target lesions was observed in two patients compared to baseline. To elucidate

these findings, we conducted CD8 and PD-L1 immunohistochemical staining on liver metastasis

biopsy specimens from some patients pre- and post-treatment (**Fig 3D-E**). The analysis revealed

increased infiltration of T cells and improved immune microenvironment following treatment, aligning

with our prior analytical findings.

Additional immune signatures analysis in predicting tumor response

We conducted gene expression analysis based on 12 predefined gene sets associated with

immunotherapy and prognosis (**Figure 4A**). Notably, samples from the responder group exhibited

higher expression of immune activation related genes compared to the non-responder group, include

effector T cells (T-eff), T cell-Inflamed, IFN-γ , cytotoxic, Cytolytic activity score (CYT), chemokines,

angiogenesis (AG), APC co-stimulation (APC co-sti), inflammation promoting (Inflam-pro), T cell

co-stimulation (T cell co-sti), parainflammation (parainflam) and tumor-infiltrating lymphocytes (TIL)

(**Figure 4A**).

Further compared the related-signature score, we found the responders had higher APC and T cell

co-stimulation signature scores compared with the non-responder group **(Figure 4B**). Moreover, the

responders had higher T cell-Inflamed, inflammation promoting and parainflammation signature

scores compared with the non-responder group (**Figure 4C**). Additionally, increased expression of

effector T cell, cytotoxicity, IFN-γ production, and cytolytic activity and TIL signature scores compared

with the non-responder group (**Figure 4D**).

Further functional insights into differential gene expression between responder and non-responder

groups were gained through gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and

Genomes (KEGG) pathway analyses. GO analysis highlighted enrichment in cytokine and

chemokine receptor activities, alongside increased T cell and leukocyte proliferation and activation

levels in responders (**Figure 4-figure supplementary1 A**). Correspondingly, KEGG analysis

underscored enrichment in pathways involving antigen processing and presentation, T cell receptor

signaling, chemokine interactions, and cytokine signaling (**Figure 4-figure supplementary1 B**).

Notably, these results indicated responders after combination of Gamma Knife SBRT and

tislelizumab treatment will enhancing tumor antigen presentation and T cell mediated immune

response in pMMR/MSS/MSI-L mCRC.

Analysis on differential expression genes before and after treatment in the responders.

To unravel the mechanisms driving tumor regression in the responder cohort, we conducted comprehensive gene expression analysis before and after treatment, focusing on 7 gene groups known for their potential inhibitory effects on immunotherapy. Post-treatment analysis revealed significant reductions in exhausted T cells, Th2 cells, and Treg cells, indicative of a favorable shift away from a suppressive immune microenvironment (**Figure 5A**). Tumor resistance mechanisms, such as fibrosis and angiogenesis, play pivotal roles in limiting therapeutic efficacy(20,21). Initially, evaluation of immunotherapy-related gene groups in partial responders versus non-responders highlighted significantly higher angiogenesis scores in the former, albeit with no significantly difference (**Figure 5B**). Recognizing potential biases from pooling samples pre- and post-treatment, we conducted separate analyses within the responder group, expanding our gene set to include fibrosis-related genes. The findings underscored substantial inhibition of both angiogenesis and fibrosis within the tumor microenvironment following SBRT, targeted therapy, and immunotherapy (**Figure 5C**). We also analyzed tumor samples from select patients before and after treatment, employing immunohistochemical staining for CD31, a marker of vascular survival (**Figure 5D**). The results demonstrated a significant reduction in CD31 expression following Gamma Knife irradiation, further supporting the notion that Gamma Knife treatment, when combined with immunotherapy, can effectively inhibit tumor angiogenesis (**Figure 5E**).

Further stratified analysis of non-responder samples before and after treatment revealed no significant alterations in the expression levels of immunosuppression-related or angiogenesis/fibrosis-related gene sets (**Figure 5-figure supplementary**1). These insights

illuminate critical pathways through which combined therapies modulate the immune landscape and

enhance treatment responses in pMMR/MSS/MSI-L mCRC.

Discussion:

By successfully reaching its main endpoint, this phase II trial shows that for combined Gamma Knife

SBRT with tislelizumab greatly increases progression-free survival (PFS) in pMMR/MSS/MSI-L

mCRC, resistant to first and second-line therapies. For this patient population, the combo treatment

has shown both safety and tolerability. By overcoming resistance to first treatment plans, our study

presents a creative therapy approach for those unresponsive to conventional treatments that offers a

suitable therapeutic option improving clinical outcomes.

Among the several cancers including nasopharyngeal carcinoma, esophageal cancer, liver cancer,

and lung cancer, Tislelizumab, a new PD-1 inhibitor, has been shown especially therapeutic efficacy.

Combining tislelizumab with chemotherapy has essentially extended PFS in patients across these

cancers (22-25).While immunotherapy has proven beneficial for some patients, metastatic colorectal

cancer (mCRC) presents unique challenges. Particularly in patients with MSS/pMMR tumors, which

are marked by low immunogenicity and great resistance to immunotherapy, tumor cells in mCRC

often evade immune detection and destruction (26). By directly targeting and destroying tumor cells,

Gamma Knife SBRT presents a potential solution by releasing a significant volume of tumor

neoantigens, and improving tumor immunogenicity, so optimizing maximizing the efficacy of

subsequent immunotherapy(27). Furthermore demonstrated to extend survival in non-small cell lung

cancer (NSCLC) with patients with brain metastases is the combination of Gamma Knife SBRT and

immunotherapy (28). Still underreported, though, is the possibility of Gamma Knife SBRT coupled

with ICIs to improve the response in pMMR/MSS/MSI-L CRC.

In our clinical observations, a notable therapeutic effect was achieved in a patient treated with

combined SBRT and immunotherapy. We hypothesize that the addition of tislelizumab following

SBRT could extend progression-free survival (PFS) compared to either modality alone. Tumor

microenvironment post-radiotherapy showed significant changes revealed by sequencing analysis of

tumor samples 'both before and after combined treatment. More precisely, the microenvironment

transitioned from an immunosuppressive, angiogenesis- and fibrosis-promoting state to an

immune-enhanced, angiogenesis- and fibrosis-attenuated state. Comparatively to non-responders,

responders   expressed   genes   linked   to   antigen   presentation,   tumor   inflammation,   and

immune-mediated tumor killing more strongly. Further showing the activation of several signaling

pathways associated with tumor cell death, including NF-κB, TNF, and JAK-STAT pathways was

enrichment analysis. Furthermore, immunotherapy targets such as PD-L1, showed an elevation,

which supports the possibility of efficient later immunotherapy. These findings substantiate our

hypothesis that patients with MSS-type mCRC resistant to first-line treatment could benefit

significantly from the combination of stereotactic radiotherapy and immunotherapy, with enhanced

immunogenicity and a more favorable tumor microenvironment facilitating improved therapeutic

outcomes.

This trial restrictions even if its outcomes show promise. First of all, our results could be biased as a

single-arm study devoid of a control group. Second, the limited sample size and single-center design

of the study lower its statistical power hence more robust conclusions depend on bigger studies.

Furthermore, even though general survival (OS) was examined, the follow-up duration was

insufficient to establish a reliable median OS. Subgroup analysis stratified by mutation type and

metastatic site did not yield statistically significant prognostic results, likely due to limitations in both

the available patient data and the sequencing depth. Given the importance of identifying reliable

biomarkers for predicting the efficacy of Gamma Knife treatment, we attempted to address this gap

by establishing a Cox proportional hazards regression model. This model aimed to correlate specific

genetic and clinical features with treatment outcomes. Despite these efforts, no substantial or

statistically significant findings emerged from the analysis, indicating that additional data and more

comprehensive modeling may be required to uncover potential predictors of treatment response. To

address these limitations, a multi-center, randomized controlled trial with a larger cohort and

extended follow-up period is essential. This will provide a more comprehensive evaluation of the

efficacy and safety of combining Gamma Knife SBRT and tislelizumab as a later-line therapy in

pMMR/MSS/MSI-L mCRC patients.

Ultimately, for patients with pMMR/MSS/MSI-L mCRC who were unresponsive to first-line therapy

regimens, the combination of Gamma Knife SBRT with tislelizumab demonstrated a high disease

control rate (DCR) and manageable safety profile. Significant post-radiotherapy improvements in the

tumor's suppressive immune microenvironment, reduced fibrosis, normalized tumor vasculature, and

activation of the PD-1/PD-L1 checkpoint pathway revealed by biomarker analyses so improving the

efficacy of immunotherapy.

Methods

Study design and participants

This single-arm, phase II trial was conducted at the First Affiliated Hospital of Jinan University to assess the antitumor efficacy and safety of a combined regimen consisting of SBRT and tislelizumab in patients with pMMR/MSS/MSI-L-type metastatic colorectal cancer (mCRC). The study is registered with ClinicalTrials.gov (identifier: ChicTR2200011777). Eligible patients, aged 18-75 years, had confirmed metastatic colorectal cancer. MSS and RAS mutation statuses were determined through gene sequencing, while clinical staging was based on imaging examinations and intraoperative findings. A total of 20 patients were enrolled in the study, with all providing written informed consent. Detailed inclusion and exclusion criteria are available in the **Appendix**.

Procedures：

As illustrated in **Figure 1A**, eligible patients received SBRT (administered 5-6 times per week, 3-5 Gy per session) combined with tislelizumab (200 mg on day 1) was incorporated into the treatment regimen. Each three-week cycle comprised a maximum of 12 cycles of induction therapy. Patients achieving complete response (CR), partial response (PR), or stable disease (SD) transitioned to tislelizumab maintenance therapy (200 mg on day 1) until documented disease progression, death, unacceptable toxicity, or patient withdrawal of consent. Treatment response was evaluated using CT or MRI after each treatment cycle. Adverse events were systematically monitored and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).

The study enrolled 20 eligible patients on November 24, 2022 (Figure 1B). All patients received at least one dose of the prescribed regimen. As of the data cutoff date (July 24, 2024), six patients continued to receive maintenance therapy. The median follow-up duration was 15 months (range: 3.4-20.0 months, IQR: 9.6-18.2 months). Due to disease-related complications, specimens could not be obtained from four patients, resulting in 16 patients being included in the per-protocol set (PPS).

Outcomes：

The primary endpoints of the study were objective response rate (ORR) and safety, encompassing

adverse events and serious adverse events, assessed according to RECIST version 1.1. Secondary

endpoints included disease control rate (DCR) and progression-free survival (PFS). ORR was

defined as the proportion of patients who achieved a best objective response of complete response

(CR) or partial response (PR) per RECIST criteria (version 1.1). DCR was defined as the proportion

of patients who achieved CR, PR, or stable disease (SD) according to RECIST criteria (version 1.1).

PFS was defined as the time from enrollment to the first documented disease progression per

RECIST version 1.1 or to death from any cause, whichever occurred first.

CD8, PD-L1 & CD31 expression level：

Tumoral CD8 & CD31 expression was measured by immunohistochemistry (IHC) (22C3 pharmDx

assays). The sections were scored for staining intensity according to the following scale: 0 (no

staining), 1 (weak staining, light yellow), 2 (moderate staining, yellowish brown), and 3 (strong

staining, brown), with 0 and 1 considered low expression, and 2 and 3 considered high expression.

The score is divided into 4 levels according to the percentage of positive cells: $0\% \leq$ positive cell

percentage $\leq 25\%$, 1 point; $25\% <$ positive cell percentage $\leq 50\%$, 2 points; $50\% <$ positive cell

percentage$\leq 75\%$, 3 points; $75\% <$ positive cell percentage$\leq 100\%$, 4 points. IHC score = cell staining

intensity score x positive cell percentage score. The PD-L1 combined positive score (CPS) was

defined as the number of PD-L1 positive cells (tumor cells, lymphocytes, macrophages) as a

proportion of the total number of tumor cells multiplied by 100. Positive PD-L1 expression was

considered when the CPS was >1.

Nanostring panel RNA sequencing：

Due to disease-related limitations, specimens could not be obtained from four patients, resulting in a

cohort of 16 patients for combined analysis. Tumor tissue samples were collected both before

treatment (BT) and after treatment (AT). Gene expression of each sample was measured using the

NanoString nCounter platform (NanoString Technologies, Seattle, WA). The quantitative

transcriptome data were obtained based on the 289-immuno-gene panel, which includes 289 genes

related to the tumor, tumor microenvironment, and immune responses in cancer. The samples that

passed the quality control (QC), which included Imaging QC, Binding Density QC, Positive Control

Linearity QC, and Positive Normalization QC can be processed in further analysis. Statistical

analyses were conducted using R (version 3.6.1). The raw count data of 289 genes were normalized

using the R package NanoStringNorm according to the geometric mean of five housekeeping genes.

The log2 transformation was then performed on the normalized data. Differentially expressed genes

were identified using the "DEseq2" package, employing criteria of log2|fold change| > 1 and false

discovery rate < 0.05. Heatmaps depicting the expression patterns of these differentially expressed

genes were generated using the "ComplexHeatmap" package.

Cox Proportional Hazards Model

Statistical analyses were conducted using R (version 3.6.1). The R package "survival" was used to

generate univariate and multivariate COX analysis results, and the relevant data were saved in the

Supplementary File1.

Immune cell profile analyses and Additional immune signatures analysis

The determination of immune cell types and gene sets associated with immunotherapy response

was informed by established literature sources (29,30). We transformed each attribute (immune

signature or gene set) value (GSVA score) x_i into x_i' by the equation x_i'

$= (x_i - x_{min})/(x_{max} - x_{min})$, where x_{min} and x_{max} represent the minimum and maximum of

the ssGSEA scores for the gene set across all samples, respectively. The detailed gene signature list

can be found in the **Supplementary File2**.

Gene set enrichment and pathway analysis

The Kyoto Encyclopedia of Genes and Genomes (KEGG) / Gene Ontology (GO) enrichment

analysis was performed using the Clusterprofiler R package. The list of gene IDs was used as the

input file. The Benjamini-Hochberg method was employed to adjust the p-values. The cut-off

threshold of p-values was set to 0.05. The enrichment results were visualized by the ggplot2 R

package. The enrichment statistic was set to classic.

Statistical analyses

Progression-free survival (PFS) and OS was estimated utilizing the Kaplan-Meier method. Statistical

analyses were conducted using R (version 3.6.1). Differences between subgroups in terms of

efficacy response were assessed using the nonparametric Wilcoxon rank-sum test (Mann-Whitney U

test), while comparisons between pre- and post-treatment samples were analyzed with the Wilcoxon

signed-rank test. Confidence intervals (CIs) for response rates were calculated employing the

Clopper-Pearson method, with all reported P values being two-sided. A P value < 0.05 was

considered statistically significant.

Data availability

The data generated in this study are available within the article and its **Source data**. Additional data

or resources related to this article are available upon reasonable request from the corresponding

authors.

Acknowledgments

This research was supported by the Clinical Frontier Technology Program of the First Affiliated

Hospital of Jinan University (No. JNU1AF-CFTP-2022-a01223), the National Natural Science

Foundation of China (82204436), Natural Science Foundation of Guangdong Province

(2024A1515030010, 2022A1515011695), Science and Technology Projects in Guangzhou

(2024A03J0825).

Ethics approval and consent to participate

This trail was conducted in accordance with the Declaration of Helsinki after approval by the

Institutional Review Board of The First Affiliated Hospital of Jinan University (KY-2022-236). All

patients provided written informed consent. The ClinicalTrials.gov identifier was:

ChiCTR2200066117.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, *et al.* Global Cancer Statistics 2020:
GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer
journal for clinicians **2021**;71(3):209-49 doi 10.3322/caac.21660.

2. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, *et al.* Colorectal cancer statistics,
2020. CA: a cancer journal for clinicians **2020**;70(3):145-64 doi 10.3322/caac.21601.

3. Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. Jama
2021;325(7):669-85 doi 10.1001/jama.2021.0106.

4. Diagnosis, Treatment Guidelines For Colorectal Cancer Working Group C. Chinese Society of Clinical Oncology
(CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version). Chinese journal of
cancer research = Chung-kuo yen cheng yen chiu **2019**;31(1):117-34 doi 10.21147/j.issn.1000-9604.2019.01.07.

5. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, *et al.* Colon Cancer, Version 2.2021,
NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN
2021;19(3):329-59 doi 10.6004/jnccn.2021.0012.

6. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nature
reviews Drug discovery **2014**;13(11):828-51 doi 10.1038/nrd4389.

7. Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, *et al.* Outcome according to
KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in
metastatic colorectal cancer by the AIO colorectal cancer study group. Annals of oncology : official journal of
the European Society for Medical Oncology **2016**;27(9):1746-53 doi 10.1093/annonc/mdw261.

8. Asaoka Y, Ijichi H, Koike K. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England journal
of medicine **2015**;373(20):1979 doi 10.1056/NEJMc1510353.

9. Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, *et al.* Immunotherapy in colorectal cancer:
rationale, challenges and potential. Nature reviews Gastroenterology & hepatology **2019**;16(6):361-75 doi
10.1038/s41575-019-0126-x.

10. Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances
and future directions. Molecular cancer **2022**;21(1):28 doi 10.1186/s12943-021-01489-2.

11. Limagne E, Euvrard R, Thibaudin M, Rébé C, Derangère V, Chevriaux A, *et al.* Accumulation of MDSC and Th17
Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug
Treatment Regimen. Cancer research **2016**;76(18):5241-52 doi 10.1158/0008-5472.Can-15-3164.

12. Hamid MA, Pammer LM, Lentner TK, Doleschal B, Gruber R, Kocher F, *et al.* Immunotherapy for
Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?
Current oncology reports **2024** doi 10.1007/s11912-024-01583-w.

13. Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, *et al.* Upfront FOLFOXIRI plus
bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer
(AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet Oncology
2022;23(7):876-87 doi 10.1016/s1470-2045(22)00274-1.

14. Papiez L, Timmerman R, DesRosiers C, Randall M. Extracranial stereotactic radioablation: physical principles.
Acta oncologica (Stockholm, Sweden) **2003**;42(8):882-94 doi 10.1080/02841860310013490.

15. Mac Manus M, Lamborn K, Khan W, Varghese A, Graef L, Knox S. Radiotherapy-associated neutropenia and
thrombocytopenia: analysis of risk factors and development of a predictive model. Blood **1997**;89(7):2303-10.

16. Singh AK, Winslow TB, Kermany MH, Goritz V, Heit L, Miller A, *et al.* A Pilot Study of Stereotactic Body Radiation
Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Clinical cancer
research : an official journal of the American Association for Cancer Research **2017**;23(17):5055-65 doi

503   10.1158/1078-0432.Ccr-16-2946.

504   17.   Choi CW, Jeong MH, Park YS, Son CH, Lee HR, Koh EK. Combination Treatment of Stereotactic Body Radiation
505   Therapy and Immature Dendritic Cell Vaccination for Augmentation of Local and Systemic Effects. Cancer
506   research and treatment **2019**;51(2):464-73 doi 10.4143/crt.2018.186.

507   18.   Morinaga N, Tanaka N, Shitara Y, Ishizaki M, Yoshida T, Kouga H, *et al.* Ten-Year Survival of a Patient Treated with
508   Stereotactic Gamma Knife Radiosurgery for Brain Metastases from Colon Cancer with Ovarian and Lymph Node
509   Metastases: A Case Report. Case reports in gastroenterology **2016**;10(1):199-206 doi 10.1159/000445976.

510   19.   Liu S, Zhang Y, Lin Y, Wang P, Pan Y. Case report: The MSI-L/p-MMR metastatic rectal cancer patient who failed
511   systemic therapy responds to anti-PD-1 immunotherapy after stereotactic body radiation-therapy. Frontiers in
512   immunology **2022**;13:981527 doi 10.3389/fimmu.2022.981527.

513   20.   Herzog BH, Baer JM, Borcherding N, Kingston NL, Belle JI, Knolhoff BL, *et al.* Tumor-associated fibrosis impairs
514   immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer. Science
515   translational medicine **2023**;15(699):eadh8005 doi 10.1126/scitranslmed.adh8005.

516   21.   Kopecka J, Salaroglio IC, Perez-Ruiz E, Sarmento-Ribeiro AB, Saponara S, De Las Rivas J, *et al.* Hypoxia as a driver
517   of resistance to immunotherapy. Drug resistance updates : reviews and commentaries in antimicrobial and
518   anticancer chemotherapy **2021**;59:100787 doi 10.1016/j.drup.2021.100787.

519   22.   Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen N, *et al.* Tislelizumab plus chemotherapy as first-line treatment for
520   recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). Cancer cell
521   **2023**;41(6):1061-72.e4 doi 10.1016/j.ccell.2023.04.014.

522   23.   Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, *et al.* Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as
523   First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
524   JAMA oncology **2021**;7(5):709-17 doi 10.1001/jamaoncol.2021.0366.

525   24.   Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, *et al.* Tislelizumab Versus Chemotherapy as Second-Line
526   Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized
527   Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
528   **2022**;40(26):3065-76 doi 10.1200/jco.21.01926.

529   25.   Qin S, Kudo M, Meyer T, Bai Y, Guo Y, Meng Z, *et al.* Tislelizumab vs Sorafenib as First-Line Treatment for
530   Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA oncology
531   **2023**;9(12):1651-9 doi 10.1001/jamaoncol.2023.4003.

532   26.   Zhao W, Jin L, Chen P, Li D, Gao W, Dong G. Colorectal cancer immunotherapy-Recent progress and future
533   directions. Cancer letters **2022**;545:215816 doi 10.1016/j.canlet.2022.215816.

534   27.   Kievit H, Muntinghe-Wagenaar MB, Hijmering-Kappelle LBM, Hiddinga BI, Ubbels JF, Wijsman R, *et al.* Safety
535   and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in
536   advanced non-small cell lung cancer, the phase I SICI trial. Lung cancer (Amsterdam, Netherlands)
537   **2023**;178:96-102 doi 10.1016/j.lungcan.2023.02.004.

538   28.   Cho A, Untersteiner H, Hirschmann D, Shaltout A, Göbl P, Dorfer C, *et al.* Gamma Knife Radiosurgery for Brain
539   Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy. Cancers
540   **2020**;12(12) doi 10.3390/cancers12123668.

541   29.   He Y, Jiang Z, Chen C, Wang X. Classification of triple-negative breast cancers based on Immunogenomic
542   profiling. Journal of experimental & clinical cancer research : CR **2018**;37(1):327 doi
543   10.1186/s13046-018-1002-1.

544   30.   Zeng TM, Yang G, Lou C, Wei W, Tao CJ, Chen XY, *et al.* Clinical and biomarker analyses of sintilimab plus
545   gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer. Nature
546   communications **2023**;14(1):1340 doi 10.1038/s41467-023-37030-w.

547   **Figure legends**

549   **Figure 1. Clinical trial flow chart. A)** Flowchart of therapeutic regimen. **B)** Flow diagram of participants in the

550   study.

Figure 2. Clinical trial results. A) Swimmer plots of patients. **B)** Kaplan–Meier curves of OS for the

per-protocol set (N = 20). **C)** Kaplan–Meier curves of PFS for the per-protocol set (N = 20). **D)** Kaplan–Meier

curves of PFS for didn't receive immunotherapy set (control group) (N= 23) and per-protocol set (test group)

(N=20). **E)** Radiological response from patient. **F)** Waterfall plot of best percent change from baseline in patient

target lesion (N= 20). **G)** Waterfall plot of best percent change from baseline in patient off-target lesion (N= 12).

559 **Figure 2-figure supplementary1. Supplementary Clinical trial results.** **A)** Kaplan–Meier curves of PFS for

560 RAS wite-type set (n= 9), KRAS set (n= 5) and NRAS set (n=6). **B)** Kaplan–Meier curves of PFS for simple

561 Liver metastasis (n= 10) and othe metastasis (n= 10). **C)** Schematic diagram of isodose lines of the planned

562 treatment volume (PTV).

Figure 3. Differential expressed genes analysis. A) Specimens collection flowchart. **B)** Transcriptome

analysis on differential expression genes between responders (PR) (n = 9) and non-responders (Non-PR) (n =

7), DESeq2 was provided to perform differential expression testing. **C)** The abundance of predefined 12

immune cells composition before and after treatment between responders (PR) (n = 9) and non-responders

(Non-PR) (n = 7), Wilcoxon test was used to determine the statistical significance between subgroups. **D&E)**

Representative CD8 & PD-L1 IHC staining of before and after treatment specimens of patient.

573 **Figure 3-figure supplementary1. Supplementary Differential expressed genes analysis.   A)**

574 Transcriptome analysis on differential expression genes before and after treatment between non-responders

575 (Non-PR) (n = 7 and responders (PR) (n = 9), DESeq2 was provided to perform differential expression testing.

576 **B)** Venn diagram of two groups of differentially expressed genes.

Figure 4. Additional immune signatures analysis. A) The expression of 12 gene sets previously reported to be associated with response to immunotherapy and prognosis between responders (PR) (n = 18) and non-responders (Non-PR) (n = 14). **BCD)** 11 gene sets of prognostic value were differentially expressed between responders (PR) (n = 18) and non-responders (Non-PR) (n = 14), box plots are indicated in terms of minima, maxima, centre, bounds of box and whiskers (interquartile range value), and percentile in the style of Tukey, Wilcoxon test was used to determine the statistical significance between subgroups.

Figure 4-figure supplementary1. GO enrichment and KEGG pathways analysis of differential

expression genes. **A)** GO enrichment analysis were performed to identify the biological process, cellular

component and molecular function of differential expression genes. **B)** H KEGG enrichment analysis of

differential expression genes.

Figure 5. Comparison of responders before and after treatment A) The expression of 7 gene sets

previously reported to be associated with response to immunosuppressive between before treatment (n = 9)

and after treatment (n = 9) in the responders (PR). **B)** The expression of Angiogenesis sets between

responders (PR) (n = 18) and non-responders (Non-PR) (n = 14). **C)** The expression of Angiogenesis &

Fibroblasts sets between before treatment (n = 9) and after treatment (n = 9) in the responders. Box plots are

indicated in terms of minima, maxima, centre, bounds of box and whiskers (interquartile range value), and

percentile in the style of Tukey, Wilcoxon test was used to determine the statistical significance between

subgroups. **D&E)** Representative CD31 IHC staining of before and after treatment specimens of patien

Figure 5-figure supplementary1. Comparison of non-responders before and after treatment.

Appendix

Participants

Inclusion criteria included the presence of at least one measurable lesion assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients must have received first-line treatment with fluorouracil, irinotecan, and oxaliplatin (any combination) or have been intolerant to first-line drugs.

KPS≥60，PS≤2. Patients were also required to have an expected survival of ≥3 months and adequate

organ and bone marrow function (absolute neutrophil count >1000/L, hemoglobin >75 g/L, neutrophils ≥

1000/μl，blood cells ≥ 75,000/μl，platelet count >100×109/L, prothrombin time <1.5 upper limit of normal

(ULN), activated partial thromboplastin time <1.5 ULN, bilirubin ≤1.5×ULN (could be extended to 3×ULN in case of liver metastasis), blood aspartate aminotransferase and alanine aminotransferase ≤3×ULN (could be extended to 5×ULN in case of liver metastasis), serum creatinine level ≤1.58×ULN or creatinine clearance ≥40 mL/min, urinary protein / creatinine ratio < 1 (or urine analysis < 1 + or 24-hour urinary protein < 1g / 24 h). Patients were excluded in the following cases: received previous treatment with any radiation therapy;, received treatment with corticosteroids or other immunosuppressive agents within 14 days prior to study drug administration, presence of autoimmune disease, known interstitial lung disease, and those with previous or concurrent malignancies expect for basal cell carcinoma, cutaneous squamous cell carcinoma, or cervical carcinoma in situ that have undergone radical treatment.

A list of 289 genes of Nanostring panel RNA sequencing.

SDHA	ITGAL	TNFSF13B	CTSW	PTGER4	GNLY
C1QB	PSMB10	HSD11B1	IRF1	CXCR2	PDCD1LG2
BTLA	C1QA	GZMA	TDO2	HERC6	ABCF1
TGFB1	LYZ	ITGA1	CD28	IL17A	IL6
GUSB	CD274	CXCR3	AXL	IL15	FPR1
TNFSF9	IL4	PDCD1	IFI35	CD3D	CD74
ICOS	KIR2DL3	SELL	IL10RA	CD1C	G6PD
PECAM1	IL7R	BRCA1	CCR5	EOMES	EGFR
SPIB	IL21R	CD40	TFRC	TLR7	HLA-DMB
IFIH1	IL2RG	IFIT2	ENTPD1	LY9	HLA-DPA1
MTOR	FCGR2B	HLA-DQA2	ITGAE	HAVCR2	IRF4
TRAT1	CD70	NOS2	LCK	IFNG	CDKN2A
DLL4	CD3E	CD79A	CCR2	FCRL2	EIF2AK2
NFKBIA	RB1	CD68	KIR3DL2	MS4A2	CTAG1B
ADM	HLA-DMA	GZMB	CCL20	CSF3R	MS4A1
HLA-DOB	S100A9	CCL18	MAGEA12	CXCL12	NT5E
CXCL11	CYBB	CD86	TNF	IFIT1	PTPRC
CCR4	CPA3	FGF13	FUT4	ICOSLG	IL2
CD40LG	CD209	CCL22	IFI27	VEGFA	BRCA2
CD163	NKG7	CCL2	STAT4	TLR9	IL12RB2

PRF1	CD44	IL2RB	ITGAM	CXCL9	TBP
CD244	CXCR4	PTEN	TNFRSF9	MRC1	CXCL1
GZMH	SNAI1	MS4A4A	TCL1A	TNFSF18	IDO1
CD247	VTCN1	MKI67	CCL21	TIGIT	ATM
CD48	PSMB9	LILRB2	CSF2	PDGFB	IL18
IL10	TNFSF10	SIGLEC5	VCAM1	HDC	MAGEA4
ANGPT2	PMS2	TAP1	RAD51	CD276	S100A8
CD80	CCL13	BIRC5	CD3G	ZAP70	ISG15
ZEB1	CTSS	TNFRSF14	TNFRSF18	PVR	MMP9
CD69	PIK3CA	TNFRSF4	PTGS2	BLK	IL1A
CEACAM3	CMKLR1	ARG1	S100A12	OAS3	TWIST1
CD84	PNOC	TNFRSF17	IL1B	BLM	CCL5
KLRD1	CD8A	PIK3CD	RUNX3	CSF1R	ADORA2A
IFIT3	CCL4	HLA-DOA	CX3CR1	IFI6	BRIP1
CD47	CCND1	TNFRSF1B	IRF9	SH2D1A	MAGEA1
CXCL8	IFITM2	CD38	CD27	NECTIN2	MLANA
ITGB2	TLR3	CXCL5	STAT3	AKT1	ITGAX
CTLA4	MAGEC2	PDGFA	FCGR1A	MLH1	KLRK1
TBX21	TNFRSF1A	FOXP3	MYC	TIE1	SLAMF7
MELK	GBP1	CD8B	CD79B	CD14	CXCL13
MX1	TNFSF4	CSF2RB	RORC	FCAR	CCL7
KLRB1	PTPN11	BCL2	CD2	HLA-DRA	LAG3
MSH2	KIR3DL1	TLR8	CD4	CXCL10	ICAM1
CX3CL1	FASLG	OAS2	CXCR6	HIF1A	NCAM1
GZMK	POLR2A	NCR1	NBN	OAS1	IFITM1
CD19	FAS	CD6	STAT1	MSH6	IL2RA
TPSAB1	HLA-DQA1	PRR5	GZMM	HLA-E	PF4
HLA-DRB1	UBB	OAZ1	TBC1D10B	FCGR3B	CXCL2
STK11IP					